—

{{First Name}} {{Last Name}}, {{Credentials}}—Let's do more for premenopausal women with mBC

For more than 20 years, few large clinical trials have been solely dedicated to premenopausal women with advanced breast cancer.¹

•	Young women with advanced breast cancer have a poorer prognosis than older women²

	-	Progression typically occurs within 1 year^3,4

	-	Tumors are more likely to be larger and of a higher grade²

•	These young women face specific challenges, including induction of premature menopause, emotional distress, and strain on their professional and personal lives^5,6


	Novartis is dedicated to building a high standard of evidence specific to young women living with advanced breast cancer

Explore our research

References: 1. ClinicalTrials.‌gov. Search results for premenopausal metastatic breast cancer studies recruiting, active, not recruiting, completed, enrolling by invitation. ht‌tps‌://clinicaltrials.‌gov/ct2/results?term=premenopausal%2C+advanced%2C+metastatic&cond=Breast+Cancer&strd_s=01‌%2F‌01‌%2F‌1995. Accessed January 24, 2018. 2. Bleyer A, Barr R, Hayes-Lattin B, Thomttttas D, Ellis C, Anderson B; Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8(4):288-298. 3. Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92(11):903-911. 4. Carlson RW, Theriault R, Schurman CM, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol. 2010;28(25):3917‌-‌3921. 5. Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. J Clin Oncol. 2005;23(15):3322‌-‌3330. 6. Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003;21(22):4184‌-‌4193.

This is a sponsored message from DMD on behalf of Novartis Pharmaceuticals Corporation. DMD provides sponsored health care-related messages from trusted third parties. This material is intended specifically and exclusively for US health care professionals. You are receiving this e-mail because you have subscribed and agreed to receive information from a DMD e-mail list.

If you prefer not to receive further messages from this sender, please click here and confirm your request.

DMD
102‌55 W. Higgins Ro‌ad, Suit‌e 280
Rosemont, IL 60‌018

DMD Privacy Policy

Novartis Pharmaceuticals Corporation

2‌/‌18

BST-1181487